NEXT BIOMETRICS GROUP ASA financials
NEXT BIOMETRICS GROUP ASA
5967007LIEEXZXK9R405 | Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Revenue | NOK 71.6M | NOK 34.4M |
| Gross profit | NOK 39.2M | NOK 7.4M |
| Operating expenses | NOK 85.2M | NOK 73.8M |
| Employee benefits expense | NOK 32.8M | NOK 42.4M |
| Raw materials & consumables used | NOK 32.4M | NOK 27.0M |
| Depreciation & amortisation | NOK 5.4M | NOK 7.1M |
| Operating profit (EBIT) | -NOK 46.1M | -NOK 66.4M |
| Net finance income / (cost) | NOK 1.0M | NOK 918.0K |
| Finance costs | NOK 119.0K | NOK 62.0K |
| Profit before tax | -NOK 45.0M | -NOK 65.5M |
| Income tax expense | NOK 197.0K | NOK 234.0K |
| Profit for the year | -NOK 45.2M | -NOK 65.7M |
| — attributable to owners | -NOK 45.2M | -NOK 65.7M |
| Total comprehensive income | -NOK 38.9M | -NOK 64.6M |
| Per share | ||
| Basic EPS | NOK -0.42 | NOK -0.69 |
| Diluted EPS | NOK -0.42 | NOK -0.69 |
| Cash flow statement | ||
| Net cash from operating activities | -NOK 61.7M | -NOK 56.6M |
| Income taxes paid | NOK 0 | NOK 26.0K |
| Net cash from investing activities | -NOK 597.0K | -NOK 13.0K |
| Net cash from financing activities | NOK 58.1M | NOK 54.9M |
| Lease liability payments | NOK 2.0M | NOK 2.1M |
| Net change in cash | -NOK 4.2M | -NOK 1.7M |
| Balance sheet | ||
| Total assets | NOK 152.4M | NOK 118.9M |
| Non-current assets | NOK 7.9M | NOK 8.3M |
| Property, plant & equipment | NOK 7.1M | NOK 6.7M |
| Current assets | NOK 144.5M | NOK 110.6M |
| Inventories | NOK 17.7M | NOK 23.1M |
| Trade & other receivables | NOK 56.8M | NOK 12.3M |
| Total equity | NOK 118.9M | NOK 94.4M |
| Non-current liabilities | NOK 2.2M | NOK 194.0K |
| Lease liabilities (non-current) | NOK 2.2M | NOK 194.0K |
| Current liabilities | NOK 31.3M | NOK 24.4M |
| Lease liabilities (current) | NOK 1.8M | NOK 1.7M |
| Derived metrics | ||
| Operating margin | -64.4% | -193.2% |
| Net margin | -63.2% | -191.2% |
| Return on equity | -38.1% | -69.7% |
| Cash conversion ratio | 1.36× | 0.86× |
| Other reported items | ||
| Adjustments For Decrease Increase In Inventories | NOK 5.8M | NOK 3.9M |
| Adjustments For Decrease Increase In Trade Account Receivable | -NOK 44.5M | -NOK 6.0M |
| Adjustments For Depreciation and Amortisation Expense | NOK 5.4M | NOK 7.1M |
| Adjustments For Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | NOK 0 | NOK 1.1M |
| Adjustments For Increase Decrease In Trade Account Payable | NOK 4.9M | -NOK 1.8M |
| Adjustments For Sharebased Payments | NOK 3.2M | NOK 5.9M |
| Cash | NOK 62.9M | NOK 67.8M |
| Comprehensive Income Attributable To Owners of Parent | -NOK 38.9M | -NOK 64.6M |
| Current Tax Liabilities Current | NOK 92.0K | NOK 33.0K |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -NOK 679.0K | NOK 155.0K |
| Equity and Liabilities | NOK 152.4M | NOK 118.9M |
| Finance Income | NOK 1.5M | NOK 1.1M |
| Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss | -NOK 332.0K | -NOK 74.0K |
| Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | NOK 0 | NOK 1.1M |
| Increase Decrease Through Sharebased Payment Transactions | NOK 3.2M | NOK 5.9M |
| Intangible Assets Other Than Goodwill | NOK 825.0K | NOK 1.5M |
| Interest Paid Classified As Operating Activities | NOK 141.0K | NOK 303.0K |
| Interest Received Classified As Operating Activities | NOK 1.4M | NOK 1.1M |
| Issue of Equity | NOK 62.4M | NOK 60.1M |
| Issued Capital | NOK 115.2M | NOK 104.0M |
| Other Comprehensive Income | NOK 6.4M | NOK 1.2M |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | NOK 6.4M | NOK 1.2M |
| Other Current Assets | NOK 7.1M | NOK 7.5M |
| Other Current Liabilities | NOK 18.4M | NOK 16.6M |
| Other Expense By Nature | NOK 47.0M | NOK 23.2M |
| Other Inflows Outflows of Cash Classified As Operating Activities | NOK 8.8M | -NOK 6.6M |
| Other Reserves | NOK 35.2M | NOK 32.0M |
| Proceeds From Issuing Shares | NOK 60.1M | NOK 57.0M |
| Retained Earnings | -NOK 101.8M | -NOK 72.5M |
| Share Issue Related Cost | NOK 2.3M | NOK 3.1M |
| Share Premium | NOK 70.3M | NOK 30.9M |
| Trade and Other Current Payables To Trade Suppliers | NOK 10.9M | NOK 6.0M |
Every line item above is a fact tagged in NEXT BIOMETRICS GROUP ASA's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (NOK), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.